Search

Your search keyword '"Bennakhi, Abdullah"' showing total 32 results
Start Over Author "Bennakhi, Abdullah"
32 results on '"Bennakhi, Abdullah"'

3. Diabetes and Ramadan: Practical guidelines 2021

Author

Hassanein, Mohamed, Afandi, Bachar, Yakoob Ahmedani, Muhammad, Mohammad Alamoudi, Reem, Alawadi, Fatheya, Bajaj, Harpreet S., Basit, Abdul, Bennakhi, Abdullah, El Sayed, Adel A., Hamdy, Osama, Hanif, Wasim, Jabbar, Abdul, Kleinebreil, Line, Lessan, Nader, Shaltout, Inass, Mohamad Wan Bebakar, Wan, Abdelgadir, Elamin, Abdo, Sarah, Al Ozairi, Ebaa, Al Saleh, Yousef, Alarouj, Monira, Ali, Tomader, Ali Almadani, Abdulrazzaq, Helmy Assaad-Khalil, Samir, Bashier, Alaaeldin Mohammed K., Arifi Beshyah, Salem, Buyukbese, Mehmet Akif, Ahmad Chowdhury, Tahseen, Norou Diop, Said, Samir Elbarbary, Nancy, Elhadd, Tarik A., Eliana, Fatimah, Ezzat Faris, MoezAlIslam, Hafidh, Khadija, Hussein, Zanariah, Iraqi, Hinde, Kaplan, Walid, Khan, Tayyab S., Khunti, Kamlesh, Maher, Salma, Malek, Rachid, Malik, Rayaz A., Mohamed, Mafauzy, Sayed Kamel Mohamed, Mesbah, Ahmed Mohamed, Nazeer, Pathan, Sameer, Rashid, Fauzia, Sahay, Rakesh K., Taha Salih, Bashir, Sandid, Mohamad A., Shaikh, Shehla, Slim, Ines, Tayeb, Khaled, Mohd Yusof, Barakatun-Nisak, and Binte Zainudin, Sueziani

Published
2022
Full Text
View/download PDF

4. International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes

Author

Bergman, Michael, primary, Manco, Melania, additional, Satman, Ilhan, additional, Chan, Juliana, additional, Schmidt, Maria Inês, additional, Sesti, Giorgio, additional, Vanessa Fiorentino, Teresa, additional, Abdul-Ghani, Muhammad, additional, Jagannathan, Ram, additional, Kumar Thyparambil Aravindakshan, Pramod, additional, Gabriel, Rafael, additional, Mohan, Viswanathan, additional, Buysschaert, Martin, additional, Bennakhi, Abdullah, additional, Pascal Kengne, Andre, additional, Dorcely, Brenda, additional, Nilsson, Peter M., additional, Tuomi, Tiinamaija, additional, Battelino, Tadej, additional, Hussain, Akhtar, additional, Ceriello, Antonio, additional, and Tuomilehto, Jaakko, additional

Published
2024
Full Text
View/download PDF

7. The characteristics and pattern of care for the type 2 diabetes mellitus population in the MENA region during Ramadan: An international prospective study (DAR-MENA T2DM)

Author

Hassanein, Mohamed, Al Awadi, Fatheya F., El Hadidy, Khaled El Sayed, Ali, Sobia Sabir, Echtay, Akram, Djaballah, Khier, Dessapt-Baradez, Cecile, Khazaal, Faris Abdul Kareem, Abu-Hijleh, Mohamad Omar, Al Shaikh, Abdulrahman, Gharbi, Mohamed El Hassan, Shehadeh, Naim, Bennakhi, Abdullah, and Al Arouj, Monira

Published
2019
Full Text
View/download PDF

9. Abstract #1305594: Real-Life Effectiveness and Care Patterns of Diabetes Management in Eastern Europe, Middle East, and Africa (RECAP-DM EEMEA STUDY)

Author

Sieberhagen, Adrian, primary, Tayeb, Khalid, additional, Al Sifri, Saud, additional, Shestakova, Marina, additional, Amod, Aslam, additional, Zakaria, Ebtesam, additional, Azzouz, Malha, additional, Assaad-Khalil, Samir, additional, Harb, Salah, additional, Malek, Rachid, additional, Al Arouj, Monira, additional, Bennakhi, Abdullah, additional, Olegovna, Ten, additional, Voss, Bernd, additional, Loulou, Maysoon, additional, and Myrga, Zankel, additional

Published
2022
Full Text
View/download PDF

12. Safety Assessment of Glucose-Lowering Drugs and Importance of Structured Education during Ramadan : A Systematic Review and Meta-Analysis

Author

Shiju, Rashmi, Akhil, Ayesha, Thankachan, Smitha, Tuomilehto, Jaakko, Al Arouj, Monira, Bennakhi, Abdullah, and Department of Public Health

Subjects
Article Subject, VILDAGLIPTIN, GLYCEMIC CONTROL, 3121 General medicine, internal medicine and other clinical medicine, MUSLIM PATIENTS, SULFONYLUREA, MANAGEMENT, TYPE-2 DIABETIC-PATIENTS, INHIBITORS, EFFICACY, FASTING MONTH, INSULIN GLARGINE
Abstract

Background. Ramadan is the sacred month of the Islamic Hijri (lunar) calendar, and during this entire month, healthy adult Muslims abstain from eating and drinking from dawn to sunset. Muslims with Type 2 Diabetes Mellitus (T2DM) who choose to fast during Ramadan encounter major risks such as hypoglycemia, hyperglycemia, diabetic ketoacidosis, dehydration, and thrombosis. Although patients with poor glycemic control and on multiple insulin injections are at high risk and exempt from fasting, many still insist on it. Thus, healthcare professionals play a pivotal role in managing diabetes-related complications in patients who fast during Ramadan. However, there is a lack of standard guidelines to be followed in association with structured education and administration of drugs and dosage. Therefore, we performed a systematic review and meta-analysis of the literature to determine the safety and efficacy of different classes of drugs and the importance of structured education during Ramadan. Methods. In this review, an extensive PubMed search was performed to obtain literature on T2DM patients who fast during the month of Ramadan until the year 2020. Preference was given to fully downloadable articles. The articles were extracted based on the eligibility criteria. The extracted data were analyzed using Review Manager software version 5.3. Results. A total of 32 articles were included for the review and 7 studies for meta-analysis. Majority of the studies demonstrated the importance of structured education either as a group session or as a one-on-one session with the healthcare professionals in preventing diabetes-related risks during Ramadan. As far as glucose-lowering drugs are concerned, DPP-4 inhibitor combined with metformin remains the drug of choice for T2DM patients who fast during Ramadan. The newer class of glucose-lowering agents appear to lower the risk of hypoglycemia in comparison with sulphonylureas, while among sulphonylureas gliclazide is relatively safe. The meta-analysis indicates that DPP-4 inhibitors would significantly reduce the risk of hypoglycemia as compared to sulphonylurea (odds ratio=0.38, 95% CI: 0.26 to 0.55, p < 0.00001). Conclusion. The results of our systematic review show that structured education and counselling by healthcare professionals can be an effective tool in preventing complications associated with fasting during Ramadan in people with T2DM. Additionally, the safest class of oral glucose-lowering drugs preferred during Ramadan fasting in T2DM patients is DPP-4 inhibitors.

Published
2022

20. Elevated expression of the toll like receptors 2 and 4 in obese individuals: its significance for obesity-induced inflammation

Author

Ahmad Rasheed, Al-Mass Anfal, Atizado Valerie, Al-Hubail Asma, Al-Ghimlas Fahad, Al-Arouj Monira, Bennakhi Abdullah, Dermime Said, and Behbehani Kazem

Subjects
Therapeutics. Pharmacology, RM1-950
Abstract

Abstract Background Expression profile of the toll like receptors (TLRs) on PBMCs is central to the regulation of proinflammatory markers. An imbalance in the TLRs expression may lead to several types of inflammatory disorders. Furthermore, the dynamic regulation of inflammatory activity and associated impaired production of cytokines by peripheral blood mononuclear cells (PBMCs) in obese individulas remain poorly understood. Therefore, we determined the perturbation in TLRs (TLR2 and TLR4), their adaptor proteins (MyD88, IRAK1 and TRAF6) expression in PBMCs/subcutaneous adipose tissue (AT) as well as inflammatory cytokines changes in obese individuals. Methods mRNA expression levels of TLR2, TLR4, IL-6, TNF-α and adaptor proteins were determined by RT-PCR. TLR2, TLR4 and adaptor proteins expression in AT was determined by immunohistochemistry. Results Obese and overweight individuals showed significantly increased expression of TLR2, TLR4 and MyD88 in both PBMCs and AT as compared with lean individuals (P Conclusions TLRs and adapter proteins were overexpressed in PBMCs from obese subjects, which correlated with increased expression of TNF-α and IL-6. This association may explain a potential pathophysiological link between obesity and inflammation leading to insulin resistance.

Published
2012
Full Text
View/download PDF

31. Association of obesity with down-regulation of heat shock protein 40 expression and evidence that exercise retrieves its normal expression

Author

Abubakr, Jehad, primary, Abu-Farha, Mohamed, additional, Al-Arouj, Monira, additional, Al-Ghimlas, Fahad, additional, Al-Khairi, Irina, additional, Al-Mudhaf, Dalal, additional, Baturcam, Engin, additional, Bennakhi, Abdullah, additional, Cherian, Preethi, additional, Hammad, Maha, additional, John, Jeena, additional, Kavalakatt, Sina, additional, Khadir, Abdelkrim, additional, Tiss, Ali, additional, Warsame, Samia, additional, Dermime, Said, additional, and Dehbi, Mohammed, additional

Published
2012
Full Text
View/download PDF

32. IL-33 is negatively associated with the BMI and confers a protective lipid/metabolic profile in nondiabetic but not diabetic subjects.

Author

Hasan, Amal, Al-Ghimlas, Fahad, Warsame, Samia, Al-Hubail, Asma, Ahmad, Rasheed, Bennakhi, Abdullah, Al-Arouj, Monera, Behbehani, Kazem, Dehbi, Mohammed, and Dermime, Said

Subjects
INTERLEUKIN-33, OBESITY, ATHEROSCLEROSIS, T helper cells, BODY mass index, INSULIN resistance
Abstract

Objective Recent studies have demonstrated a protective role for IL-33 against obesity-associated inflammation, atherosclerosis and metabolic abnormalities. IL-33 promotes the production of T helper type 2 (Th2) cytokines, polarizes macrophages towards a protective alternatively activated phenotype, reduces lipid storage and decreases the expression of genes associated with lipid metabolism and adipogenesis. Our objective was to determine the level of serum IL-33 in non-diabetic and diabetic subjects, and to correlate these levels with clinical (BMI and body weight) and metabolic (serum lipids and HbA1c) parameters. Methods The level of IL-33 was measured in the serum of lean, overweight and obese non-diabetic and diabetic subjects, and then correlated with clinical and metabolic parameters. Results Non-lean subjects had significantly (P = 0.01) lower levels of IL-33 compared to lean controls. IL-33 was negatively correlated with the BMI and body weight in lean and overweight, but not obese (non-diabetic and diabetic), subjects. IL-33 is associated with protective lipid profiles, and is negatively correlated with HbA1c, in non-diabetic (lean, overweight and obese) but not diabetic subjects. Conclusions Our data support previous findings showing a protective role for IL-33 against adiposity and atherosclerosis, and further suggest that reduced levels of IL-33 may put certain individuals at increased risk of developing atherosclerosis and insulin resistance. Therefore, IL-33 may serve as a novel marker to predict those who may be at increased risk of developing atherosclerosis. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results